Neurology
Menstrual Migraine Was Never Just Regular Migraine
Atogepant met the primary endpoint and all eight ranked secondary endpoints in a Phase III menstrual-migraine trial. The result challenges a system that has treated a predictable source of neurological disability as a secondary women’s-health problem.
FSHD Gets a Stronger Biological Signal
ALS Immunotherapy Moves Into the Extension Phase
A Rare Pain Disorder Gets a Pivotal Trial
Parkinson’s Research Takes Aim at Mitochondrial Failure
Multiple System Atrophy Gets a Clearer FDA Pathway
The WHO’s first stroke resolution turns a clinical problem into a political one
Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority
Alzheimer’s Blood Testing Moves the Disease Clock Earlier
Huntington’s Disease Gets an Oral Target-Engagement Signal
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Neurology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases